Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | Zendy

Justin Bader | Zendy; Elizabeth A. Lakota | Zendy; Glenn E. Dale | Zendy; Hélio S. Sader | Zendy; John Rex | Zendy; Paul G. Ambrose | Zendy; Sujata M. Bhavnani | Zendy

Open Access

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

Author(s) -

Justin Bader,

Elizabeth A. Lakota,

Glenn E. Dale,

Hélio S. Sader,

John Rex,

Paul G. Ambrose,

Sujata M. Bhavnani

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00318-19

Subject(s) - ertapenem , pharmacodynamics , medicine , pharmacokinetics , antibiotics , pneumonia , population , pseudomonas aeruginosa , microbiology and biotechnology , pharmacology , bacterial pneumonia , biology , antibiotic resistance , meropenem , bacteria , genetics , environmental health

Ertapenem provides activity against many pathogens commonly associated with hospital-acquired and ventilator-associated bacterial pneumoniae (HABP and VABP, respectively), including methicillin-susceptibleStaphylococcus aureus and numerous Gram-negative pathogens with one major gap in coverage,Pseudomonas aeruginosa . Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were conducted to evaluate ertapenem against the most prevalentEnterobacteriaceae causing HABP/VABP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research